$HNGE

Mecklenburg Gabriel M.I. sold $20.6M of HNGE

Mecklenburg Gabriel M.I. sold 200,000 shares of Hinge Health, Inc. (HNGE) at an average of $103.13 ($101.53–$104.34, $20.63M total) across 4 trades on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mecklenburg Gabriel M.I.
Published Oct 13, 2026, 9:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HNGE
Neutral
medium confidence
Mentioned
$HNGE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGENeutralLow
01

Why it matters

Traders may briefly reassess near-term sentiment due to the insider selling size, but without accompanying guidance, legal, or operational news, the impact is likely limited.

02

Market read

A sizable director sale ($20.63M) is newly disclosed, but the 10b5-1 context reduces the probability of a fundamental negative signal.

03

What to watch

The filing does not indicate any change in business outlook, and the director’s holdings after the transaction are listed as 0 shares, which can be driven by the plan’s scheduled execution rather than new information.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed 2026-10-13, after-hours/late session disclosure.

Background

The article is an SEC Form 4 insider transaction disclosure for Hinge Health, showing an open-market sale by a director under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$HNGENeutralMedium confidence
Context

Hinge Health director Mecklenburg Gabriel M.I. sold about 200,000 shares in an open-market transaction totaling $20.63M, per an SEC Form 4 filed today.

Expected impact

Likely mild negative bias as traders weigh insider selling, with limited follow-through risk if the 10b5-1 context is accepted.

Evidence & confidence

The filing is a primary-source Form 4 and the dollar value is sizable, but the article specifies a pre-arranged Rule 10b5-1 plan and the director has no stated operational change or guidance impact.

Market effects

Minimal, as this is company-specific insider activity with no sector-wide signal.

None.

None.

Counterpoint

The sale is consistent with a pre-arranged 10b5-1 plan, so it may reflect diversification or liquidity needs rather than a negative view of fundamentals.

Key entities

  • Hinge Health, Inc.

    Subject of the Form 4 insider sale disclosure (HNGE).

  • Mecklenburg Gabriel M.I.

    Director who executed the open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HNGEHighAI 8/10

Could Hinge Health (HNGE) Stock Win as Digital Healthcare Expands Beyond MSK Care?

Hinge Health (NYSE:HNGE) raised its 2026 revenue guidance to $856M-$860M, up from $822.16M consensus. Q2 2026 revenue grew 53% YoY to $213M, with non-GAAP operating income doubling to $62M. The company announced a $105M acquisition of Cylinder Health and expanded its share repurchase program by $300M. Analysts RBC and Truist raised price targets to $110 and $112, respectively, citing strong growth and platform expansion.

$HNGEMedAI 8/10

HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?

Hinge Health (HNGE) stock has risen 90% YTD, outperforming industry and S&P 500. Q2 revenue grew 53% YoY to $213M, with 2026 guidance raised to $856-$860M. AI and automation improved margins, while new care programs expand market reach. Analysts project 2026 EPS of $2.50 and 2027 EPS of $3.29. Growth is driven by member yield, AI efficiency, and new care offerings, but execution risks remain.

$HNGEMed

Jim Cramer says one stock hitting new highs is still a screaming buy

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.

$HNGEMed

Hinge Health (HNGE) Just Bought Its Way Into A New Market, So Now What?

Hinge Health (NASDAQ:HNGE) reported Q2 revenue of $213 million, up 53% year over year, above guidance of $200 million to $202 million. Gross margin rose to 87% and operating income to $62 million. The company said it used $105 million cash to acquire Cylinder Health for gastrointestinal care, while also expanding its migraine offering. It raised FY revenue guidance to $856 million to $860 million and authorized a $300 million buyback.

$HNGEHighAI 9/10

Why is Hinge Health stock surging today?

Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.